Top Players of Biosimilars Market With Market Size | Manufacturers With Official Website 2025

Top Players of Biosimilars Market With Market Size

In the biosimilars market, key players play a pivotal role in driving innovation and accessibility. These companies invest heavily in research and development to create biosimilars that offer similar efficacy and safety profiles compared to their reference biologics. By doing so, they contribute to reducing healthcare costs and expanding treatment options for patients. Additionally, key players engage in strategic partnerships and collaborations to enhance their market reach and streamline manufacturing processes. They also navigate through complex regulatory landscapes to ensure compliance and facilitate the entry of biosimilars into various global markets. This concerted effort by key players not only promotes competition and market growth but ultimately leads to improved patient outcomes worldwide.

As biosimilars are relatively new to the market, it is essential for these companies to provide comprehensive information and resources on their products, including their similarities and differences compared to reference biologics. This transparency allows for informed decision-making by physicians and patients, promoting trust and confidence in biosimilar treatments. As per 6Wresearch, as of 2025, the biosimilars market size is valued at approximately $32 billion. The market is projected to witness a CAGR of 24% from 2025 to 2031, reaching a value of around $110 billion by the end of the forecast period.

List of Leading Companies in the Biosimilars Market

1. Sandoz (Novartis Division)

A pioneer in the biosimilars market, Sandoz, a division of Novartis, is known for its strong portfolio and consistent growth in developing biosimilar products across various therapeutic areas such as oncology and immunology.

2. Pfizer

Pfizer has expanded its footprint in the biosimilars market through strategic acquisitions and development, offering treatments that cover a variety of medical conditions, including chronic immune diseases.

3. Amgen

As a leader in biotechnology, Amgen has leveraged its extensive experience in biologics to enter the biosimilar space, focusing on affordable therapeutic options for conditions like cancer and rheumatoid arthritis.

4. Celltrion

Celltrion is renowned for its innovative approach in the biosimilar market, particularly with its monoclonal antibody biosimilars, and continues to expand its global presence rapidly.

5. Biocon Biologics

Biocon Biologics, a subsidiary of Biocon Limited, leads in affordable biosimilar manufacturing, focusing on insulin and cancer treatments with a significant international reach.

6. Samsung Bioepis

Jointly formed by Samsung Biologics and Biogen, Samsung Bioepis is a growing player in the biosimilars market, offering alternatives in therapeutic areas such as oncology and immunology.

7. Mylan (now part of Viatris)

Mylan, now part of Viatris, has played a significant role in bringing affordable biosimilars to the market, focusing on lowering healthcare costs for major biologics.

8. Fresenius Kabi

Fresenius Kabi has expanded its product portfolio to include biosimilars, concentrating on providing high-quality, cost-effective options for complex therapies.

9. Teva Pharmaceuticals

With a strong presence globally, Teva has stepped into the biosimilars space, leveraging its extensive generics expertise to develop alternative treatment options.

10. Hoffmann-La Roche  

Roche, historically a leader in the original biologics market, has expanded to biosimilars to sustain growth and provide more treatment accessibility, particularly in oncology.

Frequently Asked Questions About the Market Study (FAQs):